Wall Street Thinks Teva Can Soar Over 60%. Here's Why Analysts Are Right.

Wall Street Thinks Teva Can Soar Over 60%. Here's Why Analysts Are Right. Teva Pharmaceutical Industries is undergoing a shift from generics and biosimilars toward novel drugs, and analysts cited by CNN Business are projecting significant upside. Every analyst polled by CNN Business has a buy rating on Teva, and 12-month price targets imply potential gains of 28% to 60% versus the current share price. The article notes Teva is down 40% over the past decade, despite the turnaround narrative. CEO Richard Francis took over in January 2023 to guide the company’s move into higher-risk drug development. In Q1 2026, revenue from generics and biosimilars was $612 million, down 28% year over year, while branded drug growth improved results. Austedo rose 41% to $559 million, and management expects full-year sales of $2.4 billion to $2.55 billion, up from $2.26 billion in 2025.